PRECSIT: A Promising Cancer Drug Target Or Biomarker (G283487)

Target Name: PRECSIT

NCBI ID: G283487

PRECSIT

Other Name(s): p53 regulated carcinoma associated Stat3 activating long intergenic non-protein coding transcript | NCRNA00346 | LINC00346 | C13orf29 | P53 regulated carcinoma associated Stat3 activating long intergenic non-protein coding transcript

PRECSIT: A Promising Cancer Drug Target Or Biomarker

Cancer is a leading cause of death worldwide, with over 20 million new cases and 50 million cancer-related deaths in 2020. The development of new treatments and therapies to combat cancer remains a major challenge in the field of cancer research.PRECSIT is a regulated carcinoma associated with Stat3 activation, a long intergenic non-protein coding transcript (lncRNA), which has been identified as a potential drug target or biomarker for cancer.

PRECSIT is a unique lncRNA that is expressed in various tissues and organs, including brain, pancreas, and gastrointestinal tract. It is highly expressed in human cancer tissues and has been associated with the development of various types of cancer, including pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and gastric ductal adenocarcinoma.

The identification of PRECSIT as a potential drug target or biomarker for cancer comes from several studies that have shown its involvement in various cancer-related processes. One of the most significant studies was published in the journal \"Oncogene\" in 2019, where researchers found that PRECSIT was highly expressed in human pancreatic cancer tissues and was associated with poor prognosis.

Another study, published in the journal \"Cancer Research\" in 2020, found that PRECSIT was overexpressed in human colorectal cancer tissues and was associated with tumor growth and metastasis.

In addition to its involvement in cancer, PRECSIT has also been shown to play a role in several non-cancer-related processes. For example, it has been shown to regulate the production of angiogenesis, a process that is critical for the formation of new blood vessels that supply tumors with oxygen and nutrients.

The identification of a potential drug target or biomarker for cancer is a significant milestone in the field of cancer research. Once identified, these targets can be used to develop new treatments and therapies that can improve outcomes for cancer patients.PRECSIT is a promising candidate for a drug target or biomarker due to its involvement in cancer and its potential to be used in the treatment of various types of cancer.

Conclusion

In conclusion, PRECSIT is a unique lncRNA that has been identified as a potential drug target or biomarker for cancer. Its involvement in various cancer-related processes and its association with the development of various types of cancer make it a promising candidate for use in cancer treatment. Further research is needed to fully understand the role of PRECSIT in cancer and to develop new treatments based on its properties.

Protein Name: P53 Regulated Carcinoma Associated Stat3 Activating Long Intergenic Non-protein Coding Transcript

The "PRECSIT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRECSIT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets